These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32722292)

  • 1. The Tumor Suppressor CYLD Inhibits Mammary Epithelial to Mesenchymal Transition by the Coordinated Inhibition of YAP/TAZ and TGF Signaling.
    Pseftogas A; Xanthopoulos K; Poutahidis T; Ainali C; Dafou D; Panteris E; Kern JG; Varelas X; Hardas A; Gonidas C; Tsingotjidou A; Hatzivassiliou E; Mosialos G
    Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32722292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YAP/TAZ regulates TGF-β/Smad3 signaling by induction of Smad7 via AP-1 in human skin dermal fibroblasts.
    Qin Z; Xia W; Fisher GJ; Voorhees JJ; Quan T
    Cell Commun Signal; 2018 Apr; 16(1):18. PubMed ID: 29695252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tead2 expression levels control the subcellular distribution of Yap and Taz, zyxin expression and epithelial-mesenchymal transition.
    Diepenbruck M; Waldmeier L; Ivanek R; Berninger P; Arnold P; van Nimwegen E; Christofori G
    J Cell Sci; 2014 Apr; 127(Pt 7):1523-36. PubMed ID: 24554433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YAP/TAZ Signaling as a Molecular Link between Fibrosis and Cancer.
    Noguchi S; Saito A; Nagase T
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30463366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
    Noto A; De Vitis C; Pisanu ME; Roscilli G; Ricci G; Catizone A; Sorrentino G; Chianese G; Taglialatela-Scafati O; Trisciuoglio D; Del Bufalo D; Di Martile M; Di Napoli A; Ruco L; Costantini S; Jakopin Z; Budillon A; Melino G; Del Sal G; Ciliberto G; Mancini R
    Oncogene; 2017 Aug; 36(32):4573-4584. PubMed ID: 28368399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the Control of TGF-β/Smad Nuclear Accumulation by the Hippo Pathway Effectors, Taz/Yap.
    Labibi B; Bashkurov M; Wrana JL; Attisano L
    iScience; 2020 Aug; 23(8):101416. PubMed ID: 32798968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ski regulates Hippo and TAZ signaling to suppress breast cancer progression.
    Rashidian J; Le Scolan E; Ji X; Zhu Q; Mulvihill MM; Nomura D; Luo K
    Sci Signal; 2015 Feb; 8(363):ra14. PubMed ID: 25670202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YAP/TAZ Are Essential for TGF-β2-Mediated Conjunctival Fibrosis.
    Futakuchi A; Inoue T; Wei FY; Inoue-Mochita M; Fujimoto T; Tomizawa K; Tanihara H
    Invest Ophthalmol Vis Sci; 2018 Jun; 59(7):3069-3078. PubMed ID: 30025139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
    Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
    Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.
    Lamar JM; Xiao Y; Norton E; Jiang ZG; Gerhard GM; Kooner S; Warren JSA; Hynes RO
    J Biol Chem; 2019 Feb; 294(7):2302-2317. PubMed ID: 30559289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers.
    Oku Y; Nishiya N; Shito T; Yamamoto R; Yamamoto Y; Oyama C; Uehara Y
    FEBS Open Bio; 2015; 5():542-9. PubMed ID: 26199863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity.
    Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW
    Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-33a Controls hMSCS Osteoblast Commitment Modulating the Yap/Taz Expression Through EGFR Signaling Regulation.
    Costa V; Carina V; Raimondi L; De Luca A; Bellavia D; Conigliaro A; Salamanna F; Alessandro R; Fini M; Giavaresi G
    Cells; 2019 Nov; 8(12):. PubMed ID: 31771093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yes-associated protein (YAP) and transcriptional coactivator with a PDZ-binding motif (TAZ): a nexus between hypoxia and cancer.
    Zhao C; Zeng C; Ye S; Dai X; He Q; Yang B; Zhu H
    Acta Pharm Sin B; 2020 Jun; 10(6):947-960. PubMed ID: 32642404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial Expression of YAP and TAZ Is Sequentially Required in Lung Development.
    Isago H; Mitani A; Mikami Y; Horie M; Urushiyama H; Hamamoto R; Terasaki Y; Nagase T
    Am J Respir Cell Mol Biol; 2020 Feb; 62(2):256-266. PubMed ID: 31486675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hippo and TGF-β interplay in the lung field.
    Saito A; Nagase T
    Am J Physiol Lung Cell Mol Physiol; 2015 Oct; 309(8):L756-67. PubMed ID: 26320155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YAP/TAZ: a promising target for squamous cell carcinoma treatment.
    Dong X; Meng L; Liu P; Ji R; Su X; Xin Y; Jiang X
    Cancer Manag Res; 2019; 11():6245-6252. PubMed ID: 31360073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YAP and TAZ are distinct effectors of corneal myofibroblast transformation.
    Muppala S; Raghunathan VK; Jalilian I; Thomasy S; Murphy CJ
    Exp Eye Res; 2019 Mar; 180():102-109. PubMed ID: 30578787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TAZ Controls
    Tiffon C; Giraud J; Molina-Castro SE; Peru S; Seeneevassen L; Sifré E; Staedel C; Bessède E; Dubus P; Mégraud F; Lehours P; Martin OCB; Varon C
    Cells; 2020 Jun; 9(6):. PubMed ID: 32545795
    [No Abstract]   [Full Text] [Related]  

  • 20. Hippo-TAZ signaling is the master regulator of the onset of triple-negative basal-like breast cancers.
    Soyama H; Nishio M; Otani J; Sakuma T; Takao S; Hara S; Masuda T; Mimori K; Toyokuni S; Lydon JP; Nakao K; Nishina H; Fukumoto T; Maehama T; Suzuki A
    Proc Natl Acad Sci U S A; 2022 Jul; 119(29):e2123134119. PubMed ID: 35858357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.